Brought to you by 
GenoScience licenses preclinical HCV candidate to BioLineRx
05 Mar 2012
Executive Summary
French antiviral drug developer GenoScience Pharma has licensed Israeli specialty pharmaco BioLineRx Ltd. exclusive worldwide rights to develop and commercialize its preclinical oral hepatitis C candidate, which BioLineRx has named BL8020.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GenoScience licenses preclinical HCV candidate to BioLineRx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice